sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
|
cephalosporins
|
diuretics
|
EFFECT
|
Cefepime_ddi.xml
|
DDI-DrugBank.d378.s1
|
DDI-DrugBank.d378.s1.p0
|
Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
|
antacid
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s6
|
DDI-DrugBank.d516.s6.p0
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
astemizole
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p8
|
Microdosed minipill progestin preparations are not recommended for use with Soriatane.
|
progestin
|
Soriatane
|
ADVISE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s6
|
DDI-DrugBank.d353.s6.p0
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
Prolixin
|
Stelazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p142
|
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
|
HEXALEN
|
antidepressants of the MAO inhibitor class
|
EFFECT
|
Altretamine_ddi.xml
|
DDI-DrugBank.d188.s0
|
DDI-DrugBank.d188.s0.p0
|
Concurrent use of tetracycline may render oral contraceptives less effective.
|
tetracycline
|
contraceptives
|
EFFECT
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s6
|
DDI-DrugBank.d500.s6.p0
|
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
|
nonsteroidal antiinflammatory agents
|
corticosteroids
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s24
|
DDI-DrugBank.d314.s24.p9
|
MAO inhibitors should be used with caution in patients receiving hydralazine.
|
MAO inhibitors
|
hydralazine
|
ADVISE
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s0
|
DDI-DrugBank.d31.s0.p0
|
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
|
Trileptal
|
contraceptive
|
MECHANISM
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s40
|
DDI-DrugBank.d307.s40.p4
|
Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
|
CMI
|
phenobarbital
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s7
|
DDI-DrugBank.d238.s7.p0
|
Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
|
Norepinephrine
|
Amphetamines
|
NONE
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s18
|
DDI-DrugBank.d158.s18.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Nizoral
|
temazepam
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p580
|
Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
|
Cyclosporine
|
Itraconazole
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s16
|
DDI-DrugBank.d165.s16.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
protease inhibitors
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p18
|
The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
|
antiplatelet medication
|
anticoagulant medication
|
ADVISE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s91
|
DDI-DrugBank.d64.s91.p0
|
The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
|
dexamethasone
|
Aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s10
|
DDI-DrugBank.d382.s10.p0
|
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
|
Anticoagulants
|
anticoagulant
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s43
|
DDI-DrugBank.d143.s43.p3
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
haloperidol
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p8
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Felbatol
|
prednisolone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p486
|
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
|
corticosteroids
|
methotrexate
|
NONE
|
7635041.xml
|
DDI-MedLine.d11.s4
|
DDI-MedLine.d11.s4.p7
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
diltiazem
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p63
|
Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
|
ZYVOX
|
vasopressor
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s2
|
DDI-DrugBank.d441.s2.p5
|
Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
|
anti-malarial drugs
|
carbamazepine
|
EFFECT
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s16
|
DDI-DrugBank.d94.s16.p2
|
Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
|
Amphetamines
|
phenytoin
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s21
|
DDI-DrugBank.d158.s21.p2
|
In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
|
propranolol
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s9
|
DDI-DrugBank.d565.s9.p0
|
Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
|
Accutane
|
tetracyclines
|
EFFECT
|
Isotretinoin_ddi.xml
|
DDI-DrugBank.d163.s2
|
DDI-DrugBank.d163.s2.p9
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
antipsychotics
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p7
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
clindamycin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p21
|
Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
|
Auranofin
|
penicillamine
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s1
|
DDI-DrugBank.d374.s1.p0
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
antidepressants
|
propafenone
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p11
|
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
|
haloperidol
|
3H-spiroperidol
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s0
|
DDI-MedLine.d15.s0.p24
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
disopyramide
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
desipramine
|
triazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p502
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
thiazides
|
contraceptives
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p4
|
Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
|
phenytoin
|
ciprofloxacin
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s14
|
DDI-DrugBank.d123.s14.p2
|
Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
|
L-glutamine
|
human growth hormone
|
MECHANISM
|
L-Glutamine_ddi.xml
|
DDI-DrugBank.d66.s0
|
DDI-DrugBank.d66.s0.p2
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
androgens
|
perphenazine
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p28
|
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
|
corticosteroids
|
H2 antagonists
|
NONE
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s12
|
DDI-DrugBank.d288.s12.p6
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
tranquilizers
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p25
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
terbutaline
|
thyroid hormones
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p80
|
Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
|
labetalol
|
calcium antagonist
|
ADVISE
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s11
|
DDI-DrugBank.d412.s11.p0
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
coumarins
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p5
|
Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
|
reserpine
|
beta-blocking agents
|
EFFECT
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s0
|
DDI-DrugBank.d388.s0.p2
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
nefazodone
|
nelfinavir
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p21
|
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
|
AEDs
|
levetiracetam
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s13
|
DDI-DrugBank.d212.s13.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
zidovudine
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p14
|
WelChol decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
|
WelChol
|
verapamil
|
MECHANISM
|
Colesevelam_ddi.xml
|
DDI-DrugBank.d551.s2
|
DDI-DrugBank.d551.s2.p0
|
Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
|
ACE inhibitors
|
beta-adrenergic blockers
|
EFFECT
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s12
|
DDI-DrugBank.d561.s12.p2
|
In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
|
VIOXX
|
warfarin
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s33
|
DDI-DrugBank.d210.s33.p0
|
Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
|
diflunisal
|
sulindac
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s26
|
DDI-DrugBank.d132.s26.p2
|
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
|
clarithromycin
|
digoxin
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s3
|
DDI-DrugBank.d450.s3.p9
|
Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
|
ketoconazole
|
phenytoin
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s22
|
DDI-DrugBank.d458.s22.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
tetracyclines
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p3
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
aminosalicylic acid
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p18
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
Antacids
|
neomycin
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p2
|
Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
|
erythromycin
|
digoxin
|
MECHANISM
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s20
|
DDI-DrugBank.d522.s20.p3
|
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
|
enalapril
|
diuretic
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s1
|
DDI-DrugBank.d107.s1.p1
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
fluvoxamine
|
quinupristin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p241
|
Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
|
Ketoconazole
|
TIKOSYN
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s10
|
DDI-DrugBank.d558.s10.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
antithyroid drugs
|
thiazide diuretics
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p235
|
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
|
BREVIBLOC
|
succinylcholine
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s10
|
DDI-DrugBank.d422.s10.p2
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
omeprazole
|
dasatinib
|
EFFECT
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p20
|
During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
|
labetalol HCl
|
halothane
|
EFFECT
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s7
|
DDI-DrugBank.d412.s7.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ibuprofen
|
indomethacin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p957
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
paroxetine
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p3
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Flupenthixol
|
MAOI
|
INT
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p1
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
dicumarol
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p5
|
Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
|
clonidine hydrochloride
|
tricyclic antidepressants
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s0
|
DDI-DrugBank.d495.s0.p0
|
Concomitant administration of clarithromycin with pimozide is contraindicated.
|
clarithromycin
|
pimozide
|
ADVISE
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s14
|
DDI-DrugBank.d29.s14.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
salicylates
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p16
|
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.
|
3H-spiroperidol
|
apomorphine
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s2
|
DDI-MedLine.d15.s2.p0
|
Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
|
WELLBUTRIN
|
cyclophosphamide
|
INT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s3
|
DDI-DrugBank.d5.s3.p1
|
Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
|
thyroid products
|
imipramine
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s15
|
DDI-DrugBank.d54.s15.p3
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
|
dihydroergotamine
|
naratriptan
|
ADVISE
|
Naratriptan_ddi.xml
|
DDI-DrugBank.d478.s1
|
DDI-DrugBank.d478.s1.p8
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
astemizole
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p12
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylurea
|
monoamine oxidase inhibitors
|
EFFECT
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p6
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
ethyl alcohol
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p1
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
warfarin
|
aliskiren
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p29
|
Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
|
Atorvastatin
|
norethindrone
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s16
|
DDI-DrugBank.d485.s16.p3
|
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
|
Robinul
|
phenothiazines
|
EFFECT
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s0
|
DDI-DrugBank.d510.s0.p1
|
Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
|
antacids
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s5
|
DDI-DrugBank.d516.s5.p7
|
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
|
cyclosporin
|
TAXOL
|
ADVISE
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s11
|
DDI-DrugBank.d288.s11.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
alcohol
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p106
|
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
|
atorvastatin
|
erythromycin
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s9
|
DDI-DrugBank.d140.s9.p5
|
Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
|
cefdinir
|
Maalox TC
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s0
|
DDI-DrugBank.d420.s0.p9
|
Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
|
anticoagulants
|
thyroid
|
ADVISE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s2
|
DDI-DrugBank.d54.s2.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
temazepam
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p40
|
The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
|
methyldopa
|
sympathomimetics
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s3
|
DDI-DrugBank.d448.s3.p3
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
retinoids
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p13
|
Coadministration of NIZORAL Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
NIZORAL
|
midazolam
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s12
|
DDI-DrugBank.d458.s12.p0
|
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
|
rifampicin
|
exemestane
|
MECHANISM
|
Exemestane_ddi.xml
|
DDI-DrugBank.d435.s2
|
DDI-DrugBank.d435.s2.p3
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
simethicone
|
antacids
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p33
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
protriptyline
|
d-amphetamine
|
NONE
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s8
|
DDI-DrugBank.d236.s8.p8
|
Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
|
Thyroxine
|
norepinephrine
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s21
|
DDI-DrugBank.d54.s21.p4
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
alfentanil
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p3
|
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
|
vincristine
|
antiretroviral
|
NONE
|
11148572.xml
|
DDI-MedLine.d115.s2
|
DDI-MedLine.d115.s2.p53
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
enflurane
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p7
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
fluconazole
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p5
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
methylphenidate
|
CMI
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p10
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.